Cyclic Tripeptide-based Potent and Selective Human SIRT5 Inhibitors

Author(s): Yanhong Jiang, Weiping Zheng*

Journal Name: Medicinal Chemistry

Volume 16 , Issue 3 , 2020


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Background: SIRT5 is one of the seven members (SIRT1-7) of the mammalian sirtuin family of protein acyl-lysine deacylase enzymes. In recent years, important regulatory roles of SIRT5 in (patho)physiological conditions (e.g. metabolism and cancer) have been increasingly demonstrated. For a better biological understanding and therapeutic exploitation of the SIRT5- catalyzed deacylation reaction, more effort on identifying potent and selective SIRT5 inhibitors beyond those currently known would be rewarding.

Objective: In the current study, we would like to see if it would be possible to develop potent and selective SIRT5 inhibitory lead compounds with a novel structural scaffold than those of the currently known potent and selective SIRT5 inhibitors.

Methods: In the current study, six N-terminus-to-side chain cyclic tripeptides (i.e. 8-13) each harboring the thiourea-type catalytic mechanism-based SIRT5 inhibitory warhead Nε-carboxyethylthiocarbamoyl- lysine as the central residue were designed, synthesized by the Nα-9- fluorenylmethoxycarbonyl (Fmoc) chemistry-based solid phase peptide synthesis (SPPS) on the Rink amide 4-methylbenzhydrylamine (MBHA) resin, purified by the semi-preparative reversedphase high performance liquid chromatography (RP-HPLC), characterized by the high-resolution mass spectrometry (HRMS); and were evaluated by the in vitro sirtuin inhibition assay and the in vitro proteolysis assay.

Results: Among the cyclic tripeptides 8-13, we found that 10 exhibited a potent (IC50 ~2.2 μM) and selective (≥60-fold over the SIRT1/2/3/6-catalyzed deacylation reactions) inhibition against the SIRT5-catalyzed desuccinylation reaction. Moreover, 10 was found to exhibit a ~42.3-fold stronger SIRT5 inhibition and a greater proteolytic stability than its linear counterpart 14.

Conclusion: With a novel and modular structural scaffold as compared with those of all the currently reported potent and selective SIRT5 inhibitors, 10 could be also a useful and feasible lead compound for the quest for superior SIRT5 inhibitors as potential chemical/pharmacological probes of SIRT5 and therapeutics for human diseases in which SIRT5 desuccinylase activity is upregulated.

Keywords: Sirtuin, SIRT5, inhibitor, cyclic tripeptide, catalytic mechanism-based, desuccinylation.

[1]
Greiss, S.; Gartner, A. Sirtuin/Sir2 phylogeny, evolutionary considerations and structural conservation. Mol. Cells, 2009, 28(5), 407-415.
[http://dx.doi.org/10.1007/s10059-009-0169-x] [PMID: 19936627]
[2]
Imai, S.; Armstrong, C.M.; Kaeberlein, M.; Guarente, L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature, 2000, 403(6771), 795-800.
[http://dx.doi.org/10.1038/35001622] [PMID: 10693811]
[3]
Li, Y.; Zhou, Y.; Wang, F.; Chen, X.; Wang, C.; Wang, J.; Liu, T.; Li, Y.; He, B. SIRT4 is the last puzzle of mitochondrial sirtuins. Bioorg. Med. Chem., 2018, 26(14), 3861-3865.
[http://dx.doi.org/10.1016/j.bmc.2018.07.031] [PMID: 30033389]
[4]
Hu, X.; Zheng, W. Chemical probes in sirtuin research.Progress in Molecular Biology and Translational Science, Sirtuins in Health and Disease; 1st; Zheng, W., Ed.; Academic Press: USA, 2018, 154, pp. 1-24.
[http://dx.doi.org/10.1016/bs.pmbts.2017.11.014]
[5]
Rajabi, N.; Galleano, I.; Madsen, A.S.; Olsen, C.A. Targeting sirtuins: substrate specificity and inhibitor design. Progress in Molecular Biology and Translational Science, Sirtuins in Health and Disease; 1st; Zheng, W., Ed.; Academic Press: USA, 2018, 154, pp. 25-69.
[http://dx.doi.org/10.1016/bs.pmbts.2017.11.003]
[6]
Li, S.; Zheng, W. Mammalian sirtuins SIRT4 and SIRT7.Progress in Molecular Biology and Translational Science, Sirtuins in Health and Disease; 1st; Zheng, W., Ed.; Academic Press: USA, 2018, 154, pp. 147-168.
[http://dx.doi.org/10.1016/bs.pmbts.2017.11.001]
[7]
Carabetta, V.J.; Cristea, I.M. Regulation, function, and detection of protein acetylation in bacteria. J. Bacteriol., 2017, 199(16), e00107-e00117.
[http://dx.doi.org/10.1128/JB.00107-17] [PMID: 28439035]
[8]
Bheda, P.; Jing, H.; Wolberger, C.; Lin, H. The substrate specificity of sirtuins. Annu. Rev. Biochem., 2016, 85, 405-429.
[http://dx.doi.org/10.1146/annurev-biochem-060815-014537] [PMID: 27088879]
[9]
Chen, B.; Zang, W.; Wang, J.; Huang, Y.; He, Y.; Yan, L.; Liu, J.; Zheng, W. The chemical biology of sirtuins. Chem. Soc. Rev., 2015, 44(15), 5246-5264.
[http://dx.doi.org/10.1039/C4CS00373J] [PMID: 25955411]
[10]
Martínez-Redondo, P.; Vaquero, A. The diversity of histone versus nonhistone sirtuin substrates. Genes Cancer, 2013, 4(3-4), 148-163.
[http://dx.doi.org/10.1177/1947601913483767] [PMID: 24020006]
[11]
Kumar, S.; Lombard, D.B. Functions of the sirtuin deacylase SIRT5 in normal physiology and pathobiology. Crit. Rev. Biochem. Mol. Biol., 2018, 53(3), 311-334.
[http://dx.doi.org/10.1080/10409238.2018.1458071] [PMID: 29637793]
[12]
Elkhwanky, M.S.; Hakkola, J. Extranuclear sirtuins and metabolic stress. Antioxid. Redox Signal., 2018, 28(8), 662-676.
[http://dx.doi.org/10.1089/ars.2017.7270] [PMID: 28707980]
[13]
Bringman-Rodenbarger, L.R.; Guo, A.H.; Lyssiotis, C.A.; Lombard, D.B. Emerging roles for SIRT5 in metabolism and cancer. Antioxid. Redox Signal., 2018, 28(8), 677-690.
[http://dx.doi.org/10.1089/ars.2017.7264] [PMID: 28707979]
[14]
Sebastián, C.; Mostoslavsky, R. The role of mammalian sirtuins in cancer metabolism. Semin. Cell Dev. Biol., 2015, 43, 33-42.
[http://dx.doi.org/10.1016/j.semcdb.2015.07.008] [PMID: 26238985]
[15]
Choi, J.E.; Mostoslavsky, R. Sirtuins, metabolism, and DNA repair. Curr. Opin. Genet. Dev., 2014, 26, 24-32.
[http://dx.doi.org/10.1016/j.gde.2014.05.005] [PMID: 25005742]
[16]
Dai, Y.; Faller, D.V. Transcription regulation by class III histone deacetylases (HDACs)-sirtuins. Transl. Oncogenomics, 2008, 3, 53-65.
[PMID: 21566744]
[17]
Neo, S.H.; Tang, B.L. Sirtuins as modifiers of huntington's disease (HD) pathology. Progress in Molecular Biology and Translational Science, Sirtuins in Health and Disease; 1st; Zheng, W., Ed.; Academic Press: USA, 2018, 154, pp. 105-145.
[18]
Schiedel, M.; Robaa, D.; Rumpf, T.; Sippl, W.; Jung, M. The current state of NAD+-dependent histone deacetylases (sirtuins) as novel therapeutic targets. Med. Res. Rev., 2018, 38(1), 147-200.
[http://dx.doi.org/10.1002/med.21436] [PMID: 28094444]
[19]
Jiang, Y.; Liu, J.; Chen, D.; Yan, L.; Zheng, W. Sirtuin inhibition: strategies, inhibitors, and therapeutic potential. Trends Pharmacol. Sci., 2017, 38(5), 459-472.
[http://dx.doi.org/10.1016/j.tips.2017.01.009] [PMID: 28389129]
[20]
Dai, H.; Sinclair, D.A.; Ellis, J.L.; Steegborn, C. Sirtuin activators and inhibitors: Promises, achievements, and challenges. Pharmacol. Ther., 2018, 188, 140-154.
[http://dx.doi.org/10.1016/j.pharmthera.2018.03.004] [PMID: 29577959]
[21]
He, B.; Du, J.; Lin, H. Thiosuccinyl peptides as Sirt5-specific inhibitors. J. Am. Chem. Soc., 2012, 134(4), 1922-1925.
[http://dx.doi.org/10.1021/ja2090417] [PMID: 22263694]
[22]
Roessler, C.; Nowak, T.; Pannek, M.; Gertz, M.; Nguyen, G.T.; Scharfe, M.; Born, I.; Sippl, W.; Steegborn, C.; Schutkowski, M. Chemical probing of the human sirtuin 5 active site reveals its substrate acyl specificity and peptide-based inhibitors. Angew. Chem. Int. Ed. Engl., 2014, 53(40), 10728-10732.
[http://dx.doi.org/10.1002/anie.201402679] [PMID: 25111069]
[23]
Kalbas, D.; Liebscher, S.; Nowak, T.; Meleshin, M.; Pannek, M.; Popp, C.; Alhalabi, Z.; Bordusa, F.; Sippl, W.; Steegborn, C.; Schutkowski, M. Potent and selective inhibitors of human sirtuin 5. J. Med. Chem., 2018, 61(6), 2460-2471.
[http://dx.doi.org/10.1021/acs.jmedchem.7b01648] [PMID: 29494161]
[24]
Liu, J.; Huang, Y.; Zheng, W. A selective cyclic peptidic human SIRT5 inhibitor. Molecules, 2016, 21(9) E1217
[http://dx.doi.org/10.3390/molecules21091217] [PMID: 27626398]
[25]
Rajabi, N.; Auth, M.; Troelsen, K.R.; Pannek, M.; Bhatt, D.P.; Fontenas, M.; Hirschey, M.D.; Steegborn, C.; Madsen, A.S.; Olsen, C.A. Mechanism-based inhibitors of the human sirtuin 5 deacylase: structure-activity relationship, biostructural, and kinetic insight. Angew. Chem. Int. Ed. Engl., 2017, 56(47), 14836-14841.
[http://dx.doi.org/10.1002/anie.201709050] [PMID: 29044784]
[26]
Lin, H. Thiourea compounds and their use as inhibitors of SIRT2 or SIRT5. International Publication Number WO2014/197775A1 2014.
[27]
Liu, S.; Ji, S.; Yu, Z.J.; Wang, H.L.; Cheng, X.; Li, W.J.; Jing, L.; Yu, Y.; Chen, Q.; Yang, L.L.; Li, G.B.; Wu, Y. Structure-based discovery of new selective small-molecule sirtuin 5 inhibitors. Chem. Biol. Drug Des., 2018, 91(1), 257-268.
[http://dx.doi.org/10.1111/cbdd.13077] [PMID: 28756638]
[28]
Goodman, M.; Ro, S. Peptidomimetics for drug design.Burger’s Medicinal Chemistry and Drug Discovery; Principles and Practice, 5th; Wolff, M.E., Ed.; John Wiley & Sons: USA, 1995, 1, pp. 803-861.
[29]
Zang, W.; Hao, Y.; Wang, Z.; Zheng, W. Novel thiourea-based sirtuin inhibitory warheads. Bioorg. Med. Chem. Lett., 2015, 25(16), 3319-3324.
[http://dx.doi.org/10.1016/j.bmcl.2015.05.058] [PMID: 26081291]
[30]
Hirsch, B.M.; Hao, Y.; Li, X.; Wesdemiotis, C.; Wang, Z.; Zheng, W. A mechanism-based potent sirtuin inhibitor containing Nε-thiocarbamoyl-lysine (TuAcK). Bioorg. Med. Chem. Lett., 2011, 21(16), 4753-4757.
[http://dx.doi.org/10.1016/j.bmcl.2011.06.069] [PMID: 21752644]
[31]
Avalos, J.L.; Celic, I.; Muhammad, S.; Cosgrove, M.S.; Boeke, J.D.; Wolberger, C. Structure of a Sir2 enzyme bound to an acetylated p53 peptide. Mol. Cell, 2002, 10(3), 523-535.
[http://dx.doi.org/10.1016/S1097-2765(02)00628-7] [PMID: 12408821]
[32]
Hirsch, B.M.; Gallo, C.A.; Du, Z.; Wang, Z.; Zheng, W. Discovery of potent, proteolytically stable, and cell permeable human sirtuin peptidomimetic inhibitors containing Nε-thioacetyl-lysine. MedChemComm, 2010, 1, 233-238.
[http://dx.doi.org/10.1039/c0md00089b]
[33]
Dixon, M. The determination of enzyme inhibitor constants. Biochem. J., 1953, 55(1), 170-171.
[http://dx.doi.org/10.1042/bj0550170] [PMID: 13093635]
[34]
Pronase: Product Description. 2006. And references cited therein. 2006.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 3
Year: 2020
Published on: 16 April, 2020
Page: [358 - 367]
Pages: 10
DOI: 10.2174/1573406415666190603101937
Price: $65

Article Metrics

PDF: 24
HTML: 4